As metabolic dysfunction-associated steatohepatitis (MASH) emerges as one of the most dangerous and underdiagnosed drivers of ...

Echosens and Boehringer Ingelheim have expanded their collaboration aimed at expediting progress in metabolic ...

This expansion will change the trajectory of MASH by focusing on early detection, diagnosis, and access to care.

By combining their diagnostic and therapeutic expertise, Echosens and Boehringer Ingelheim aim to help close persistent gaps ...

WALTHAM, Mass. & FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Echosens North America, a high-technology company offering the FibroScan ® portfolio of solutions, and ChronWell, a digital health and ...

PARIS, Aug. 26, 2024 /PRNewswire/ -- Echosens is thrilled to unveil the inaugural Liver Health Super Shaper Award, a heartfelt initiative designed to celebrate the extraordinary medical ...

WESTBOROUGH, Mass., Dec. 9, 2024 /PRNewswire/ -- Echosens, the leader in liver health, is proud to be recognized as one of the 2024 Top Places to Work in Massachusetts, earning a spot among the ...

Echosens SA obtained clearance from the U.S. FDA to expand the indications for screening with its Fibroscan system. The approval removes contraindications for pregnancy and active implant and includes ...

PARIS, March 26, 2024 /PRNewswire/ -- Echosens announced today the appointment of Victor de Lédinghen, MD PhD, as the company's new Chief Medical Officer. With over two decades of clinical ...

By combining their diagnostic and therapeutic expertise, Echosens and Boehringer Ingelheim aim to help close persistent gaps in awareness, real-world evidence, and clinical adoption. This next ...